Progress and perspective of inorganic nanoparticle-based siRNA delivery systems

Expert Opinion on Drug Delivery

Volumn 13, Issue 4, 2016, Pages 547-559

  Jiang, Ying ^a   Huo, Shuaidong ^a,b   Hardie, Joseph ^a   Liang, Xing Jie ^b   Rotello, Vincent M ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

Author keywords

Cancer therapy; inorganic nanoparticle; RNAi; siRNA delivery; surface chemistry

Indexed keywords

CALCIUM PHOSPHATE NANOPARTICLE; GOLD NANOPARTICLE; INORGANIC COMPOUND; MAGNETIC NANOPARTICLE; MESOPOROUS SILICA NANOPARTICLE; NANOPARTICLE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

BIOCOMPATIBILITY; BIODEGRADATION; COVALENT BOND; CYTOSOL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; ENDOSOME; GENE SILENCING; HUMAN; LIPID BILAYER; NANOENCAPSULATION; PHYSICAL CHEMISTRY; REVIEW; RNA INTERFERENCE; STATIC ELECTRICITY; SURFACE PROPERTY; TUMOR VOLUME; CHEMISTRY; METABOLISM;

CYTOSOL; HUMANS; NANOPARTICLES; RNA, SMALL INTERFERING; SURFACE PROPERTIES;

EID: 84961197137     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2016.1134486     Document Type: Review

References (77)

1. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998; 391 (6669): 806-811. 10.1038/35888
2. Leung RK, Whittaker PA. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther. 2005; 107 (2): 222-239. 10.1016/j.pharmthera.2005.03.004
3. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev. 2007; 59 (2-3): 75-86. 10.1016/j.addr.2007.03.005
4. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009; 8 (2): 129-138. 10.1038/nrd2742
5. Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther. 2006; 13 (6): 541-552. 10.1038/sj.gt.3302703
6. Burnett JC, Rossi JJ. RNA-based therapeutics: current progress and future prospects. Chem Biol. 2012; 19 (1): 60-71. 10.1016/j.chembiol.2011.12.008
7. Roth L. First evidence of RNA interference mechanism induced in human: getting closer to a cure? Cell Adh Migr. 2011; 5 (1): 1-3
8. He S, Zhang D, Cheng F, et al. Applications of RNA interference in cancer therapeutics as a powerful tool for suppressing gene expression. Mol Biol Rep. 2009; 36 (8): 2153-2163. 10.1007/s11033-008-9429-7
9. Oh Y-K, Park TG. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev. 2009; 61 (10): 850-862. 10.1016/j.addr.2009.04.018
10. Schiffelers RM, Ansari A, Xu J, et al. Cancer siRNA therapy by tumor selective delivery with ligand-Targeted sterically stabilized nanoparticle. Nucleic Acids Res. 2004; 32 (19): e149. 10.1093/nar/gnh140
11. Yuan X, Naguib S, Wu Z. Recent advances of siRNA delivery by nanoparticles. Expert Opin Drug Deliv. 2011; 8 (4): 521-536. 10.1517/17425247.2011.559223
12. Yin H, Kanasty RL, Eltoukhy AA, et al. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014; 15 (8): 541-555. 10.1038/nrg3763
13. Hiruta C, Toyota K, Miyakawa H, et al. Development of a microinjection system for RNA interference in the water flea Daphnia pulex. BMC Biotechnol. 2013; 13 (1): 96. 10.1186/1472-6750-13-96
14. Tomar RS, Matta H, Chaudhary PM. Use of adeno-Associated viral vector for delivery of small interfering RNA. Oncogene. 2003; 22 (36): 5712-5715. 10.1038/sj.onc.1206733
15. Barton GM, Medzhitov R. Retroviral delivery of small interfering RNA into primary cells. Proc Natl Acad Sci USA. 2002; 99 (23): 14943-14945. 10.1073/pnas.242594499
16. Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat Rev Genet. 2007; 8 (8): 573-587. 10.1038/nrg2141
17. Wagner E. Polymers for siRNA delivery: inspired by viruses to be targeted, dynamic, and precise. Acc Chem Res. 2012; 45 (7): 1005-1013. 10.1021/ar2002232
18. Wang M, Alberti K, Varone A, et al. Enhanced intracellular siRNA delivery using bioreducible lipid-like nanoparticles. Adv Health Mater. 2014; 3 (9): 1398-1403. 10.1002/adhm.v3.9
19. Galaway FA, Stockley PG. MS2 viruslike particles: a robust, semisynthetic targeted drug delivery platform. Mol Pharm. 2013; 10 (1): 59-68. 10.1021/mp3003368
20. Van Asbeck AH, Beyerle A, McNeill H, et al. Molecular parameters of siRNA-cell penetrating peptide nanocomplexes for efficient cellular delivery. ACS Nano. 2013; 7 (5): 3797-3807. 10.1021/nn305754c
21. Conde J, Ambrosone A, Hernandez Y, et al. 15 years on siRNA delivery: beyond the state-of-The-Art on inorganic nanoparticles for RNAi therapeutics. Nano Today. 2015; 10: 421-450. 10.1016/j.nantod.2015.06.008
22. Dominska M, Dykxhoorn DM. Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci. 2010; 123 (Pt 8): 1183-1189. 10.1242/jcs.066399
23. Ma D. Enhancing endosomal escape for nanoparticle mediated siRNA delivery. Nanoscale. 2014; 6 (12): 6415-6425. 10.1039/c4nr00018h
24. Sokolova V, Epple M. Inorganic nanoparticles as carriers of nucleic acids into cells. Angew Chem Int Ed. 2008; 47 (8): 1382-1395. 10.1002/(ISSN)1521-3773
25. Zhang L, Li Y, Yu JC. Chemical modification of inorganic nanostructures for targeted and controlled drug delivery in cancer treatment. J Mater Chem B. 2014; 2 (5): 452-470. 10.1039/C3TB21196G
26. Zhao MX, Zeng EZ, Zhu BJ. The biological applications of inorganic nanoparticle drug carriers. Chem Nano Mat. 2015; 1 (2): 82-91
27. Ding Y, Jiang Z, Saha K, et al. Gold nanoparticles for nucleic acid delivery. Mol Ther. 2014; 22 (6): 1075-1083. 10.1038/mt.2014.30
28. Pissuwan D, Niidome T, Cortie MB. The forthcoming applications of gold nanoparticles in drug and gene delivery systems. J Control Release. 2011; 149 (1): 65-71. 10.1016/j.jconrel.2009.12.006
29. Han G, Ghosh P, Rotello VM. Functionalized gold nanoparticles for drug delivery. Nanomedicine. 2007; 2 (1): 113-123. 10.2217/17435889.2.1.113
30. Ho D, Sun X, Sun S. Monodisperse magnetic nanoparticles for theranostic applications. Acc Chem Res. 2011; 44 (10): 875-882. 10.1021/ar200090c
31. Lim E-K, Kim T, Paik S, et al. Nanomaterials for theranostics: recent advances and future challenges. Chem Rev. 2015; 115 (1): 327-394. 10.1021/cr300213b
32. Rana S, Bajaj A, Mout R, et al. Monolayer coated gold nanoparticles for delivery applications. Adv Drug Deliv Rev. 2012; 64 (2): 200-216. 10.1016/j.addr.2011.08.006
33. Jensen SA, Day ES, Ko CH, et al. Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med. 2013; 5 (209): 209ra152
34. Randeria PS, Seeger MA, Wang XQ, et al. siRNA-based spherical nucleic acids reverse impaired wound healing in diabetic mice by ganglioside GM3 synthase knockdown. Proc Natl Acad Sci USA. 2015; 112 (18): 5573-5578. 10.1073/pnas.1505951112
35. Huang X, Hu Q, Braun GB, et al. Light-Activated RNA interference in human embryonic stem cells. Biomaterials. 2015; 63: 70-79. 10.1016/j.biomaterials.2015.06.006
36. Lee JS, Green JJ, Love KT, et al. Gold, poly(beta-Amino ester) nanoparticles for small interfering RNA delivery. Nano Lett. 2009; 9 (6): 2402-2406. 10.1021/nl9009793
37. Conde J, Tian F, Hernandez Y, et al. In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models. Biomaterials. 2013; 34 (31): 7744-7753. 10.1016/j.biomaterials.2013.06.041
38. Son S, Nam J, Kim J, et al. i-Motif-driven Au nanomachines in programmed siRNA delivery for gene-silencing and photothermal ablation. ACS Nano. 2014; 8 (6): 5574-5584. 10.1021/nn5022567
39. Kim ST, Chompoosor A, Yeh YC, et al. Dendronized gold nanoparticles for siRNA delivery. Small. 2012; 8 (21): 3253-3256. 10.1002/smll.201201141
40. Lee Y, Lee SH, Kim JS, et al. Controlled synthesis of PEI-coated gold nanoparticles using reductive catechol chemistry for siRNA delivery. J Control Release. 2011; 155 (1): 3-10. 10.1016/j.jconrel.2010.09.009
41. Lee MY, Park SJ, Park K, et al. Target-specific gene silencing of layer-by-layer assembled gold-cysteamine/siRNA/PEI/HA nanocomplex. ACS Nano. 2011; 5 (8): 6138-6147. 10.1021/nn2017793
42. Lee SK, Han MS, Asokan S, et al. Effective gene silencing by multilayered siRNA-coated gold nanoparticles. Small. 2011; 7 (3): 364-370. 10.1002/smll.201001314
43. Lee SK, Tung C-H. A fabricated siRNA nanoparticle for ultralong gene silencing in vivo. Adv Funct Mater. 2013; 23 (28): 3488-3493. 10.1002/adfm.201202777
44. Guo S, Huang Y, Jiang Q, et al. Enhanced gene delivery and siRNA silencing by gold nanoparticles coated with charge-reversal polyelectrolyte. ACS Nano. 2010; 4 (9): 5505-5511. 10.1021/nn101638u
45. Lu W, Zhang G, Zhang R, et al. Tumor site-specific silencing of NF-kappaB p65 by targeted hollow gold nanosphere-mediated photothermal transfection. Cancer Res. 2010; 70 (8): 3177-3188. 10.1158/0008-5472.CAN-09-3379
46. Jiang Y, Tang R, Duncan B, et al. Direct cytosolic delivery of siRNA using nanoparticle-stabilized nanocapsules. Angew Chem Int Ed. 2015; 54 (2): 506-510
47. Lee JH, Lee K, Moon SH, et al. All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. Angew Chem Int Ed. 2009; 48 (23): 4174-4179. 10.1002/anie.200805998
48. Kumar M, Yigit M, Dai G, et al. Image-guided breast tumor therapy using a small interfering RNA nanodrug. Cancer Res. 2010; 70 (19): 7553-7561. 10.1158/0008-5472.CAN-10-2070
49. Liu G, Xie J, Zhang F, et al. N-Alkyl-PEI-functionalized iron oxide nanoclusters for efficient siRNA delivery. Small. 2011; 7 (19): 2742-2749. 10.1002/smll.201100825
50. Agrawal A, Min D-H, Singh N, et al. Functional delivery of siRNA in mice using dendriworms. ACS Nano. 2009; 3 (9): 2495-2504. 10.1021/nn900201e
51. Jiang S, Eltoukhy AA, Love KT, et al. Lipidoid-coated iron oxide nanoparticles for efficient DNA and siRNA delivery. Nano Lett. 2013; 13 (3): 1059-1064. 10.1021/nl304287a
52. Namiki Y, Namiki T, Yoshida H, et al. A novel magnetic crystal-lipid nanostructure for magnetically guided in vivo gene delivery. Nat Nanotechnol. 2009; 4 (9): 598-606. 10.1038/nnano.2009.202
53. Xia T, Kovochich M, Liong M, et al. Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. ACS Nano. 2009; 3 (10): 3273-3286. 10.1021/nn900918w
54. Li X, Chen Y, Wang M, et al. A mesoporous silica nanoparticle-PEI-fusogenic peptide system for siRNA delivery in cancer therapy. Biomaterials. 2013; 34 (4): 1391-1401. 10.1016/j.biomaterials.2012.10.072
55. Kapilov-Buchman Y, Lellouche E, Michaeli S, et al. Unique surface modification of silica nanoparticles with polyethylenimine (PEI) for siRNA delivery using cerium cation coordination chemistry. Bioconjug Chem. 2015; 26 (5): 880-889. 10.1021/acs.bioconjchem.5b00100
56. Ngamcherdtrakul W, Morry J, Gu S, et al. Cationic polymer modified mesoporous silica nanoparticles for targeted siRNA delivery to HER2+ breast cancer. Adv Funct Mater. 2015; 25 (18): 2646-2659. 10.1002/adfm.201404629
57. Chen AM, Zhang M, Wei D, et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small. 2009; 5 (23): 2673-2677. 10.1002/smll.200900621
58. Meng H, Mai WX, Zhang H, et al. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano. 2013; 7 (2): 994-1005. 10.1021/nn3044066
59. Pittella F, Zhang M, Lee Y, et al. Enhanced endosomal escape of siRNA-incorporating hybrid nanoparticles from calcium phosphate and PEG-block charge-conversional polymer for efficient gene knockdown with negligible cytotoxicity. Biomaterials. 2011; 32 (11): 3106-3114. 10.1016/j.biomaterials.2010.12.057
60. Lee MS, Lee JE, Byun E, et al. Target-specific delivery of siRNA by stabilized calcium phosphate nanoparticles using dopa-hyaluronic acid conjugate. J Control Release. 2014; 192: 122-130. 10.1016/j.jconrel.2014.06.049
61. Li J, Yang Y, Huang L. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J Control Release. 2012; 158 (1): 108-114. 10.1016/j.jconrel.2011.10.020
62. Oishi M, Nakaogami J, Ishii T, et al. Smart PEGylated gold nanoparticles for the cytoplasmic delivery of siRNA to induce enhanced gene silencing. Chem Lett. 2006; 35 (9): 1046-1047. 10.1246/cl.2006.1046
63. Giljohann DA, Seferos DS, Prigodich AE, et al. Gene regulation with polyvalent siRNA-nanoparticle conjugates. J Am Chem Soc. 2009; 131 (6): 2072-2073. 10.1021/ja808719p
64. Zheng D, Giljohann DA, Chen DL, et al. Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. Proc Natl Acad Sci USA. 2012; 109 (30): 11975-11980. 10.1073/pnas.1118425109
65. Song W-J, Du J-Z, Sun T-M, et al. Gold nanoparticles capped with polyethyleneimine for enhanced siRNA delivery. Small. 2010; 6 (2): 239-246. 10.1002/smll.200901513
66. Elbakry A, Zaky A, Liebl R, et al. Layer-by-layer assembled gold nanoparticles for siRNA delivery. Nano Lett. 2009; 9 (5): 2059-2064. 10.1021/nl9003865
67. Han L, Zhao J, Zhang X, et al. Enhanced siRNA delivery and silencing gold-chitosan nanosystem with surface charge-reversal polymer assembly and good biocompatibility. ACS Nano. 2012; 6 (8): 7340-7351. 10.1021/nn3024688
68. Gilleron J, Querbes W, Zeigerer A, et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol. 2013; 31 (7): 638-646. 10.1038/nbt.2612
69. Ding Y, Wang Y, Zhou J, et al. Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis. Biomaterials. 2014; 35 (25): 7214-7227. 10.1016/j.biomaterials.2014.05.009
70. Benjaminsen RV, Mattebjerg MA, Henriksen JR, et al. The possible proton sponge effect of polyethylenimine (PEI) does not include change in lysosomal pH. Mol Ther. 2013; 21 (1): 149-157. 10.1038/mt.2012.185
71. Hatakeyama H, Ito E, Akita H, et al. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo. J Control Release. 2009; 139 (2): 127-132. 10.1016/j.jconrel.2009.06.008
72. Park JW, Bae KH, Kim C, et al. Clustered magnetite nanocrystals cross-linked with PEI for efficient siRNA delivery. Biomacromolecules. 2011; 12 (2): 457-465. 10.1021/bm101244j
73. Slowing II, Vivero-Escoto JL, Wu C-W, et al. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008; 60 (11): 1278-1288. 10.1016/j.addr.2008.03.012
74. Bhattarai S, Muthuswamy E, Wani A, et al. Enhanced gene and siRNA delivery by polycation-modified mesoporous silica nanoparticles loaded with chloroquine. Pharm Res. 2010; 27 (12): 2556-2568. 10.1007/s11095-010-0245-0
75. Hartono SB, Gu W, Kleitz F, et al. Poly-l-lysine functionalized large pore cubic mesostructured silica nanoparticles as biocompatible carriers for gene delivery. ACS Nano. 2012; 6 (3): 2104-2117. 10.1021/nn2039643
76. Ma X, Zhao Y, Ng KW, et al. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery. Chem J Eur. 2013; 19 (46): 15593-15603. 10.1002/chem.201302736
77. Roy I, Mitra S, Maitra A, et al. Calcium phosphate nanoparticles as novel non-viral vectors for targeted gene delivery. Int J Pharm. 2003; 250 (1): 25-33